Notícias

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.

A unanimous 3-judge panel ruled that UMB Bank had standing to represent former Celgene shareholders despite a procedural error in its appointment

By Jonathan Stempel NEW YORK, Aug 13 (Reuters) - A U.S. federal appeals court said a judge erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.

The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.

Management raised its full-year forecast, but the market seems to be asking for more than a higher target.

Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.

Bristol Myers Squibb recently announced it will invest about US$2.30 billion in a new 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, Texas, expected to support production of small molecules, biologics, and antibody-drug conjugates while creating nearly 500 skilled jobs and about 2,000 construction and indirect roles through 2030. This facility’s flexible, automation-ready design and alignment with the company’s broader US$40.00 billion U.S...

PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.

RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.

One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock’s biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed […]

Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.

BMS will invest $2.3 billion in a 600,000-square-foot Houston manufacturing campus at Generation Park in Houston, Texas.

This will establish BMS’ in-house manufacturing presence in Texas, adding to its ongoing outlicensing and research partnerships in the state.

For years, healthcare and semiconductor stocks weren’t particularly tied to each other. In other words, they increasingly go in opposite directions: when chips sell off, healthcare has tended to catch a bid. After years of underperformance, healthcare investors are enjoying a burst of momentum amid the recent nervousness around AI.

During Mad Money’s August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here’s a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has […]

Bristol Myers Squibb is building a $2.3 billion drug manufacturing campus in Houston, set to create 500 jobs. Learn about the details.

The roughly 600,000-square-foot facility at Generation Park will create nearly 500 permanent jobs and about 2,000 construction positions

Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.

Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.

Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.

Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.

The space company reported record revenues and a double beat, and its potential looks astronomical.

Bristol Myers Squibb (NYSE:BMY) has unveiled plans to invest approximately $2. 3 billion in a new manufacturing campus at Generation Park in Houston, Texas, as the pharmaceutical group expands its production capabilities in the United States.

REPL's RP1 secures FDA approval for advanced melanoma, easing regulatory uncertainty. The company expands its oncolytic immunotherapy pipeline.

Surging oil prices, a CPI spike not seen in three years, and Treasury yields at levels last touched in 2007 are forcing a September rate decision that could reshape which stocks lead the market through the rest of 2026.